In this issue of the Journal, Gold and colleagues (1) describe important observations concerning the use of the thrombin inhibitor argatrobao in patients with unstable aogina. Essentially, they noted that angina recurred in 21% of the patients, geoerally between 4 and 8 h after cessation of ergatroban therapy. This editorial discusses the clinical implications and potential mechanisms of this finding.
Current Focus on Thrombin Inhibitors
Role d Uuombin In cardiac ewnts. Argatroban, a syn. thetic derivative of arginine, is one of several inhibitors of thrombin et various stages of preclinical development end clinical testing. These drugs are attracting interest for several reasons. First, it is now well established that coronary thrombus develops in the majority of acute myocardial infarctions and in many, perhaps most. cases of unstable angina (for review, see Ref. 2) . Moreover, patients with unstable angina have elevated coronary sinus levels of the platelet products thromboxane AI and serotonin (Z), as well as elevated blood levels of Rbrinopeptide A (3), which is cleaved from fibrinogen when the latter is protealytically converted to fibrin by thmmbin. Heparin and aspirin have each reduced the mortality rate of myocardial infarction and of unstable aogina (4-7). further confirming the mle of thrombin and of olatelets in the oathoaenesis of these syndromes. In add;tion, thrombotic &occ&on has proved to be a limiting factor in approximately 5% of angioplasty procedures and 10% of thmmbulytic interventions in myocardial infarction (8).
LimitationY of current MtItbmmbotic egents. Thus, a second reason for the current interest in thrombin is the recognition of the need for better aotitbrombotic regimens.
For example, warfarin is slow to act, has little effect on the extrinsic pathway, most he taken oral& and interacts with many other dmgs. Recombinant tissue plasminogen activator, by activating plasmin, activates the coagulation system by cleaving prothmmbin aad Factors V and X (9,lO:l. PIastin also activates platelets (see later) (II). Aspirin inhibits prosteglandin endoperoxide synthesis (cyctooxygenase). thereby inhibiting the formation of tbromboxane AZ, itself a platelet agonist and vaseconstrictor (12) (13) (14) . However, other agonists such as thrombin. adenosioe diphosphate. serotooin. platelet activating factor, epinephrine and collagen are not inhibited by aspirin: these act not only through the phospholipase A pathway, bat also through phospholipase C and perhaps other pathways, thereby partially circumventing the aspirin tiects p,lO,l9. Moreover, even relatively low doses of aspirin can inhibit cndothelial synthesis of orostacvclin (16). Ticlooidine has been aooroved bv the &od and Drug Admioi.&tioo for transient&heroic a&ks in asphin+ensitive patients but is bordencd with a slow onset of action and a small risk of oeutropenia (12). Heparin, which largely acts by accelerating the proteolytic ioactivation of thrombin and activated Fector X by antithrombin III fl7,18), is at a disadvantage in established thrombosis becattle it is neutralized by platelet factor 4 and throrolwspon.
din, and it has reduced ctlicacy against thrombht bound to fibrin or to platelets. In addition, heparin is a hctemgerteoos group of mokculQ extracted by a varkty of procedures and subject to lot to lot variability. Fioally, the requirement for aolithrombin III limits its utility in the of& patient with reduced levels of antIthm&in I11 (9.19). Rdedthrombh,k+cwmd&m uld&ekt-.A third reason for the recent~focus on thrhbin inhibitors is that it is now understood to be not only the tin ' "tee in the conversion of fibrinogen to fibrin. hut also a key regttlamry steoftoaetharwith activationof Factor VII andlissttefactor. or'& Factor X) in the coagulation cascade. Moreover; thrombin plays a critical role in the amplification of the cascade, activating Factors V and XIII, which eventttally kads to the generation of more thrombin. In addition, thrombin activates Factor XIII to promote clot retractioo i20.20. These effects can all be demonstrated in vitro and, although the in viva regulation of this system is not yet completely understood, it is noteworthy that the high risk period after myocardial iofarction is characterized by ongoing, low grade activation of thromhitt (22).
Finally, thmmbin is one of the most potent known agonists for platelet release and aggrcgatioa (20). Tltus, whereas any platelet inhibitor is an indirect inhibitor of coagulation (because plateler surfaces accelerate the wage- (I) indicate that one factor co&b&g to renewed .aogiw and XIII and protein C, platelet aggregation, woconstricafter argatroban iofusioo is the continued generation of tion. neotmphil adherence, monocyte chemotaxis. mitogenthmmbin during the infusion. This obseruti~~~ suggests that esis for ettdotbeliat and smooth muscle cells and lymphothe positive feedback loop (wherein lhmmbin activates cytes, sod stimolatioo of production of prwacyclin plateletFactors V and VIII, eventwily causiog activatioo of proactivatiog factor, platelet-derived growth factor and nitric thrombin to thrombin) is not critical for the sustained geeoxide (23). Thus. the e&cts of a thmmbin antagonist like eration of thnxnbii in patients tih unstabk angirt& Alterarga(mban could be diverse.
natively, thmmbin's activatiw of fibrinogen may be mere Actiox~ of cameat thmgbio iokiMloR The thrombin completely inhibited thao that of Factors V and VIII by a inhibitors that have received the most attention are hirodin given dose of argatrobao. In addition 10 cootinoed genera-(a leech peptide whose sequence is similar to one near the tion of thrombin, a second factor in the thrombincatalylic site of the tbrombin receptor) and the related aotithrombin III rebound cao be inferred from the data of hirulog and hien, as well as the synthctis inhibitors Eidt and colleagues (32), who reported that .w@rokw PPACK, EwP714 and argatroban. Experiments to date indidisplaces thromhin from antithmmbio III. 'llw. as ergacate that these inhibitors block roost if not att of thrombin's troban is a competitive (reversible) inhibitor and is hugely actions. This observation is noteworthy because it was not cleared by I h, an increase in thmmbin-antithrombin IU obvious that the catalytic site and receptor site would be complex at the end of the info&n is to be expected. physically or functionally lied:
Fibrin biis thrombin assuming that there are no dramatic changes in the binding without inhibiting thmmbin's catalytic action and several or degradation of the thmmbinargatmbatt comp!ex. reports have indicated that thmmbin cao sewe as a mitogen
Other thrombin-&ted mechanisms. Other mechanisms for smooth muscle cells, despite inactivation of the catalytic that may well contribute to the reactivatioo of angina after domain (27) . Argatroban binds to a hydrophobic pocket near cessation of argatmban infusion inch& a possl&le up the catalytic site of thrombin with moderately high &inky regulation of thrombin receptors on the platelets, as platelet (28). Its K, for inhibition of catalytic activation of fibrinogen receptors are subjected to posttraoslatiooal w&tion by is 19 nhf, ami it is almost as potent h inhibition of platelet cyclic adenosiw monophosphate and cyclic guanosine aggregation (& 40 n&f) (29). Because argatroban is small and mottophosphate. lnbibitioa of tbmmbin may also prevent binds to a dllfennt binding site from that of fibrin, it inhibits thmmbio's antitbmmbatic actions, which are mediated by clot-bound tbrombin just as hirodin does (301. In experimenactivation of protein C and stimulation of production of nitric ttd models of thrombolysis, argatrobao prevents thrombosis oxide and prostacyclio (19).
and wcelerates lysis as wetI as or better than heparin (31).
Role of cessation of hqwin therapy. Another mechanism that should be considered relates to the recent report by Theroux et al. (33) of a reactivation of angina 5 to I5 h after the cessation of heparin administration in patients with unstable angina. In the present study by Gold and cdleagues (i), six of the nine patients developing recurrent angina had been receiving hepatin until appronmateiy 4 h before argatmban infusion. In contrast, of the 34 patients who had no recurrent symptoms, only 12 had previously been taking hsparin. Thos, some of the xnctivation of angina in the present study might reflect discontinuation of the heparih is well. Moreover, increased clearance of antithrombin III durine heoarin infusion would tend to lower the baseline me&&ents of thrombin-antithrombin complex before argatroban inrusion. By the time the complex was measured again (2 h after cessation of the infusion and 10 h after discontinuation of heparin). antithrombin 111 levels would be increasing. Thus, the calculated foulfold increase in thrombin-antithrombin III complex after argatroban may be in put tiifactual.
Clittieal lmollcatiws of the current fInding. The clinical impdcations df these data are that iafusion~ of argatroban shouid not be discontinued abraotlv but should be tavered after beginning treatment With ispirin or another c&tive platelet inhibitor. Jang et al. (34) found that the addition of aspirin to mgatmban therapy acted to maintain arterial patency after thrombolytic therapy in a canine model. However, concomitant aspirin therapy will not prevent the increase in thmmbin levels after discontinuation of argatroban. The increased thmmbin could activate platelets (through pathways not blacked by aspirin) and generate librin.'Th;s. patients must be closkly imnitored for recurrent ischemia during and after the administration of a thrombin inhibitor, such as argatmban. In the canine model of cyclic flow variations, Eidt et al. (32) found that argatroban blocked cyclic flows only if given in the 1st 30 min to 2 h. When treatment was begun after 3 h of cyclic flows, the argatroban (and hcparin) were largely ineffective. However, cyclic flows were subsequently blocked by the addition of antagonists of the semtonin and lhromboxane AZ receptors. Thus, clinical studies need to be performed that evrduate the benefit &rded by the more direct thrombin antagonists when they are given relatively late after the onset ofunstable anghla.
Inhibition of the final steps (platelet aggregation. formation of fibrin) is naturallv attractive in a svstem with multiple and partialI; redundanipathways. Ho&r, as the m&c-ular defects in thrombosis are characterized, it may be possible to select specific therapies based on specific mechanisms in individual patients. For example, it is c!xr that at least some patients with unstable angina have increased generation of serotonin and thromboxane AZ (2). Some patients with recurrent venous thrombosis have deficiencies in antithmmbin 111, elevated plasminogen activator inhibitor I or deficient protein C or protein S (22). Some patients after myocardial irfarction continue to generate thrombin and fibrin. High levels of fibrinogen, hematocrit, platelet aunt, Iw density lipoprotein and lipoprotein(a) appear to be risk factors for thrombosis (22) . Thmmbosis itself probably creates a local "hepxin deficiency" due to binding of cell surface heparan sulfate by thmmbin and degradation of hepamn by platelet-derived endoglycosidases (3%. However, at the present 'ime, individualized therapy is impractical. Moreover, the likelihood is that multiple mechanisms are operating in many patients. These factors act to limit the et%acy of monotherapies as exemplified in this report by Gold et al. (I). Thus, in the foreseeable future, we are likely to be using double and triple therapy, with increasingly specific agents, to treat patients with unstable angina and to prevent its development in patients at risk.
